➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Mallinckrodt
Merck
Dow
Boehringer Ingelheim

Last Updated: September 22, 2021

DrugPatentWatch Database Preview

Claims for Patent: 5,721,133

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

Summary for Patent: 5,721,133
Title: Protease assays
Abstract:Hybrid regulatory proteins are provided which contain amino acid sequences that are susceptible to cleavage by specific proteolytic enzymes. When acted upon by such enzymes, the hybrid regulatory proteins are rendered substantially less active, thereby altering the rate of production of products of indicator genes that are controlled by the regulatory proteins. Also provided are DNAs encoding such regulatory proteins, recombinant vectors and transformed eukaryotic cells containing such DNAs, and methods for identifying inhibitors of the specific proteolytic enzymes.
Inventor(s): Dasmahapatra; Bimalendu (Nutley, NJ)
Assignee: Schering Corporation (Kenilworth, NJ)
Application Number:08/456,582
Patent Claims:1. A DNA encoding a hybrid regulatory protein comprising a DNA-binding peptide, a linker peptide, and a DNA transcription-modifying peptide, wherein the linker peptide bridges the DNA-binding peptide and the transcription-modifying peptide and is susceptible to cleavage by a specific protease that (a) is essential for replication of microbial pathogens or causes harmful effects on target tissues and organs; and (b) is not capable of cleaving the protein(s) from which the DNA-binding and transcription-modifying peptides are derived; which hybrid regulatory protein is (a) capable of binding to a specific region of DNA that controls the expression of one or more genes, thereby altering the rate of expression of the genes, and is (b) rendered substantially inactive by cleavage of the linker peptide by the protease, wherein substantially inactive means that the cleaved protein has 20% or less of the transcription-activating activity of the uncleaved, intact protein.

2. A recombinant vector comprising a DNA encoding a hybrid regulatory protein comprising a DNA-binding peptide, a linker peptide, and a DNA transcription-modifying peptide, wherein the linker peptide bridges the DNA-binding peptide and the transcription-modifying peptide and is susceptible to cleavage by a specific protease that (a) is essential for replication of microbial pathogens or causes harmful effects on target tissues and organs; and (b) is not capable of cleaving the protein(s) from which the DNA-binding and transcription-modifying peptides are derived; which hybrid regulatory protein is (a) capable of binding to a specific region of DNA that controls the expression of one or more genes, thereby altering the rate of expression of the genes, and is (b) rendered substantially inactive by cleavage of the linker peptide by the protease, wherein substantially inactive means that the cleaved protein has 20% or less of the transcription-activating activity of the uncleaved, intact protein; which recombinant vector has regulatory elements that permit the DNA to be transcribed in a eukaryotic cell.

3. The recombinant vector of claim 2 in which the DNA encodes a hybrid regulatory protein that is a repressor of DNA transcription.

4. The recombinant vector of claim 2 in which the DNA encodes a hybrid regulatory protein that is an activator of DNA transcription.

5. The recombinant vector of claim 2 in which the DNA encodes a hybrid regulatory protein wherein the linker peptide is susceptible to cleavage by Coxsackievirus 3C protease or HIV-1 protease.

6. The recombinant vector of claim 4 in which the DNA encodes a hybrid regulatory protein wherein the amino acid sequences of the DNA-binding peptide and the DNA transcription-modifying peptide correspond to amino acid sequences of GAL4.

7. The recombinant vector of claim 2 which is plasmid p1009 or pHP236, which plasmids have been deposited with the American Type Culture Collection and assigned Accession Nos. ATCC 68282 and ATCC 68,563, respectively.

8. A eukaryotic cell comprising:

(a) a DNA encoding a hybrid regulatory protein comprising a DNA-binding peptide, a linker peptide, and a DNA transcription-modifying peptide, wherein the linker peptide bridges the DNA-binding peptide and the transcription-modifying peptide and is susceptible to cleavage by a specific protease that (i) is essential for replication of microbial pathogens or causes harmful effects on target tissues and organs; and (ii) is not capable of cleaving the protein(s) from which the DNA-binding and transcription-modifying peptides are derived; which hybrid regulatory protein is (i) capable of binding to a specific region of DNA that controls the expression of one or more genes, thereby altering the rate of expression of the genes, and is (ii) rendered substantially inactive by cleavage of the linker peptide by the protease, wherein substantially inactive means that the cleaved protein has 20% or less of the transcription-activating activity of the uncleaved, intact protein;

(b) a DNA encoding a protease capable of specifically cleaving the linker peptide; and

(c) a DNA site responsive to the uncleaved hybrid regulatory protein, which DNA site is operatively linked to a reporter gene.

9. The recombinant vector of claim 2 in which the DNA is under the control of a regulatable promoter.

10. The recombinant vector of claim 6 in which the DNA encodes a hybrid protein wherein the amino acid sequences of the DNA-binding peptide and the DNA transcription-modifying peptide are the amino acid sequences of residues 1-147 and 768-881, respectively, of GAL4, as set forth in SEQ ID NO: 1.

11. The recombinant vector of claim 10 in which the hybrid gene encodes a hybrid protein wherein the linker peptide is susceptible of cleavage by Coxsackievirus 3C protease, HIV-1 protease or collagenase.

12. The recombinant vector of claim 1 in which the hybrid gene encodes a hybrid protein wherein the linker peptide is Coxsackievirus 3C protease.

13. The recombinant vector of claim 3 in which the DNA encodes a hybrid protein wherein the amino acid sequences of the DNA-binding peptide and the DNA transcription-modifying peptide correspond to amino acid sequences of the .lambda. phage repressor.

14. The eukaryotic cell of claim 8 in which the DNA is under the control of a regulatable promoter.

15. The eukaryotic cell of claim 14 in which the hybrid protein is a repressor of DNA transcription.

16. The eukaryotic cell of claim 14 in which the hybrid protein is an activator of DNA transcription.

17. The eukaryotic cell of claim 16 in which the DNA encodes a hybrid protein wherein the amino acid sequences of the DNA-binding peptide and the DNA transcription-modifying peptide correspond to amino acid sequences of GAL4.

18. The eukaryotic cell of claim 17 in which the DNA encodes a hybrid protein wherein the amino acid sequences of the DNA-binding peptide and the DNA transcription-modifying peptide are the amino acid sequences of residues 1--147 and 768-881, respectively, of GAL4, as set forth in SEQ ID NO: 1.

19. The eukaryotic cell of claim 18 in which the DNA encodes a hybrid protein wherein the linker peptide is susceptible to cleavage by Coxsackievirus 3C protease, HIV-1 protease or collagenase.

20. The eukaryotic cell of claim 19 in which the DNA encodes a hybrid protein wherein the linker peptide is susceptible to cleavage by Coxsackievirus 3C protease.

21. The eukaryotic cell of claim 20 which harbors plasmid p1009.

22. The eukaryotic cell of claim 19 in which the DNA encodes a hybrid protein wherein the linker peptide is susceptible to cleavage by HIV-1 protease.

23. The eukaryotic cell of claim 20 which harbors plasmid pHP236.

24. The eukaryotic cell of claim 8 which is a mammalian cell or a yeast cell.

25. The eukaryotic cell of claim 8 in which the measurable product is .beta.-galactosidase.

Details for Patent 5,721,133

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Smith And Nephew SANTYL collagenase OINTMENT;TOPICAL 101995 001 1965-06-04 ⤷  Free Forever Trial Schering Corporation (Kenilworth, NJ) 2015-02-24 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Medtronic
Dow
McKinsey
Mallinckrodt
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.